| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8871241 | EYEPOINT PHARMS | Injectable sustained release delivery devices |
Aug, 2027
(3 years from now) | |
| US7998108 | EYEPOINT PHARMS | Injector apparatus and method of use |
Jan, 2028
(4 years from now) | |
Yutiq is owned by Eyepoint Pharms.
Yutiq contains Fluocinolone Acetonide.
Yutiq has a total of 2 drug patents out of which 0 drug patents have expired.
Yutiq was authorised for market use on 12 October, 2018.
Yutiq is available in implant;intravitreal dosage forms.
Yutiq can be used as a method of injecting an implant.
The generics of Yutiq are possible to be released after 12 January, 2028.
Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 12 October, 2018
Treatment: A method of injecting an implant
Dosage: IMPLANT;INTRAVITREAL
YUTIQ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic